In parallel, siRNA molecules and CRISPR/Cas9 therapeutic approaches aimed against specific TDP-43-viral protein interactors could also be tested to assess their ability to revert aberrant TDP-43 pathology during viral infections, as has been tried for neurodegenerative processes [150,151]. This evidence concerns the gene TARDBP and viral infectious disease.